Wegovy and Saxenda are the two older weight-loss GLP-1s, and the gap between them is wider than most people realize. Saxenda (liraglutide) is a daily injection that averages about 8% weight loss. Wegovy (semaglutide) is a weekly injection averaging 14.9%. Same class, different generation — and the diet implications track the weight loss.
| A | B | |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Dosing | Weekly | Daily |
| Average weight loss | 14.9% (STEP 1) | ~8% (SCALE) |
| Appetite effect | Stronger, longer-acting | Weaker, wears off daily |
| Nausea reported | ~44% | ~28-40% |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
For weight loss, Wegovy by a clear margin (14.9% vs ~8%), and it is weekly instead of daily. Saxenda is a reasonable option when Wegovy is not tolerated or not covered.
Cost, coverage, and tolerability. Its lighter appetite effect can be enough for mild weight loss with fewer side effects, and the daily ritual suits some people better than a weekly shot.
Same framework, lower stakes. Protein and fiber targets are identical; the nausea risk is simply smaller, so rich foods are less of a gamble.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.